Design Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for DSGN, updated each market day.
DSGN AI Sentiment
AI sees no strong directional signal for Design Therapeutics, Inc. Common Stock stock over the next 10 market days.
Prediction date: Sept. 22, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About Design Therapeutics, Inc. Common Stock
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
Sector
Exchange
Market Cap
$801,670,949
Cap Tier
Employees
55
Headquarters
CARLSBAD, CA
Listed Since
March 26, 2021
Website
DSGN Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
DSGN Volatility
Design Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings: this can present both opportunity and risk for traders.
